Search
Palivizumab
go.drugbank.com/drugs/DB00110ApprovedInvestigationalHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Categories: Respiratory Syncytial Virus Anti-F Protein Monoclonal AntibodyProducts: SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,1 ADET, SYNAGIS 100 MG/1 ML IM ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON, 1 ADETTea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalIt may be referred to as _Melaleuca alternifolia_ oil. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].
Mixtures: I Dew Care Tea Tree O StarterkitSynonyms: Snow-in-summer leaf oil, Ti tree oilAldehyde dehydrogenase, mitochondrial
go.drugbank.com/bio_entities/BE0000133TargetEnzymeHumansIt also exhibits esterase activity that is enhanced by NAD+ but does not require it, although the physiological relevance of this activity remains unclear (PubMed:19506075)
Synonyms: ALDH INADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial
go.drugbank.com/bio_entities/BE0000485TargetHumansCore subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor
Synonyms: Complex I-51kDAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnIt is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]
Finasteride
go.drugbank.com/drugs/DB01216ApprovedInvestigational[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or
Mixtures: Finasteride 0.1% / Minoxidil 7%, Finasteride 0.1% / Minoxidil 5%Categories: Drugs Used in Benign Prostatic Hypertrophy, 5-alpha Reductase InhibitorsTeplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes. … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients
Categories: Drugs Used in DiabetesNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L39544] It was fully approved by the FDA on May 25, 2023. … [L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesLumefantrine
go.drugbank.com/drugs/DB06708ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy.
Mixtures: KOMEFAN ® 280, ARTEMETERO Y LUMEFANTRINACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors